Eisai Announces Launch of Pariet(R) Triple Formulation Combinati

Eisai Announces Launch of Pariet(R) Triple Formulation Combination Packs
Rabecure(R) 400 and 800 and Rabefine(R), for Primary and Secondary H.Pyloei
Eradication Respectively, in Japan 
Tokyo, Feb 13, 2014 - (JCN Newswire) -  Eisai Co., Ltd. announced today that it
will launch two types of triple formulation combination packs that contain its
proton pump inhibitor Pariet(R) (rabeprazole sodium) in Japan on February 14
for use in Helicobacter pylori eradication. 
The launch will feature three products: Rabecure(R) Pack 400 and Rabecure Pack
800, which package together individual blister sheets each containing a daily
triple formulation dose of Pariet, amoxicillin hydrate and clarithromycin for
use in primary H. pylori eradication, and Rabefine(R) Pack, which similarly
packages together individual blister sheets containing a daily triple
formulation dose of Pariet, amoxicillin hydrate and metronidazole for use in
secondary H. pylori eradication. Eisai received approval to manufacture and
market both combination types in Japan from the country's Ministry of
Health, Labour and Welfare in August 2013, with all three products added to
Japan's National Health Insurance drug price list on December 13 of the
same year. 
In H. pylori eradication triple therapy with Pariet and two antimicrobial
agents, successful eradication significantly depends on whether the patient
properly adheres to the prescribed treatment regimen. Taking the incorrect dose
or missing doses altogether can lead not only to reduced eradication rates but
also to bacterial resistance. With daily-dose blister sheets adopted for both
the primary and secondary eradication combinations of Eisai's new triple
formulation packs, the launch is expected to help ensure that H. pylori
eradication therapy is administered more appropriately and with greater
certainty, while also improving patient drug compliance and offering increased
convenience in a medical setting. 
Eisai believes that the launch of its Rabecure and Rabefine combination packs
will further promote the appropriate use of therapeutic agents in H. pylori
eradication therapy and contribute to a wider range of treatment options
available for gastric cancer eradication and other treatments for diseases
associated with H. pylori. 
Product details at: http://www.eisai.com/news/enews201409pdf.pdf. 
About Pariet(R) 
Pariet is a proton pump inhibitor discovered and developed by Eisai. First
launched in Japan in 1997, the drug is today approved in more than 100
countries and territories worldwide. In Japan, Pariet is indicated for multiple
uses, including for the treatment of gastric ulcer, duodenal ulcer, reflux
esophagitis, non-erosive gastroesophageal reflux disease, and as an adjunctive
therapy in various types of H. pylori eradication, including in patients with
gastric ulcer, duodenal ulcer, and H. pylori gastritis, and is available in
both 10 mg and 20 mg tablet formulations based on evidence collected in
Japanese patients. In addition, in December 2010, Eisai received approval in
Japan for additional twice-daily 10 mg and twice-daily 20 mg dosage and
administration of Pariet for treatment of patients with reflux esophagitis who
are unable to obtain satisfactory relief with conventional proton pump
inhibitor treatment. 
In November 2013, Eisai submitted an application for Pariet in Japan seeking a
further indication expansion for use in the prevention of recurrence of gastric
and duodenal ulcers during treatment with low-dose aspirin and the approval of
a new 5 mg tablet formulation. Eisai is currently also conducting a Phase III
study in Japan of Pariet as a maintenance therapy for patients with reflux
esophagitis resistant to once-daily proton pump inhibitor treatment. 
About Eisai 
Eisai Co., Ltd. (TSE: 4523; ADR: ESALY) is a research-based human health care
(hhc) company that discovers, develops and markets products throughout the
world. Eisai focuses its efforts in three therapeutic areas: integrative
neuroscience, including neurology and psychiatric medicines; integrative
oncology, which encompasses oncotherapy and supportive-care treatments; and
vascular/immunological reaction. Through a global network of research
facilities, manufacturing sites and marketing subsidiaries, Eisai actively
participates in all aspects of the worldwide healthcare system. For more
information about Eisai Co., Ltd., please visit www.eisai.com. 
Contact: 
Public Relations Department,
Eisai Co., Ltd.
+81-3-3817-5120 
Copyright 2014 JCN Newswire. All rights reserved. www.japancorp.net 
Provider ID: 00028687
 
 
Press spacebar to pause and continue. Press esc to stop.